The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection
5 affiliations
- 1Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- 2Mary Ann and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- 3Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- 4Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- 5Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
Abstract
Metastatic pancreatic ductal adenocarcinoma (PDAC) has historically been managed with systemic therapy, and local therapies have, in general, been avoided in the absence of symptoms directly related to a specific metastasis. Even if a specific site of disease, such as a local recurrence, had the potential to cause symptoms in the future, there was a bias against prophylactic palliation. It was well-established that most patients die of systemic progression. This approach is now under pressure from four directions. Retrospective case series have reported survival durations longer than anticipated in highly selected patients with low-volume, single-organ disease. A randomized phase II trial reported that metastasis-directed therapy prolonged progression-free survival. Biologic data indicate that the site of metastatic relapse is encoded in gene expression profiles already present in the primary tumor. Second-line systemic therapy has become substantially more effective, which lengthens the interval over which control of an untreated metastasis may become clinically important. We trace the oligometastatic concept from the 1995 Hellman and Weichselbaum hypothesis to the 2026 OligoPanc consensus definition of up to three lesions confined to a single organ, examine the criteria proposed for patient selection, summarize the surgical and ablative radiotherapy literature, and consider the trials that will determine whether this is a treatable disease state or a favorable prognostic phenotype. We conclude that induction systemic therapy, followed by response assessment that weighs the absence of disease progression, Carbohydrate Antigen 19-9 (CA19-9) kinetics, and performance status, is a defensible route to local therapy directed at the metastases and the primary tumor, and warrants prospective study.
Related
- Gallium-68 (68Ga)-Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Initial Staging of High-Risk Prostatic Adenocarcinoma: Reclassification to Oligometastatic Disease and Change in Treatment Intent
- Borderline resectable pancreatic ductal adenocarcinoma: a narrative review
- Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma
- Exceptionally Durable Response to First-Line S-1 Monotherapy in Metastatic Pancreatic Adenocarcinoma: A Case Report
- Prognostic and Spatial Organization of Tertiary Lymphoid Structures in Pancreatic Ductal Adenocarcinoma
BibTeX
@article{gaur2026evolution,
title = {{The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection}},
author = {Kshitij S. Gaur and William A. Hall and Mandana Kamgar and Thomas McFall and Douglas B. Evans and Y. David Seo},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203376},
url = {https://www.mdpi.com/2072-6694/18/20/3376},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection
AU - Kshitij S. Gaur
AU - William A. Hall
AU - Mandana Kamgar
AU - Thomas McFall
AU - Douglas B. Evans
AU - Y. David Seo
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203376
UR - https://www.mdpi.com/2072-6694/18/20/3376
AB - Metastatic pancreatic ductal adenocarcinoma (PDAC) has historically been managed with systemic therapy, and local therapies have, in general, been avoided in the absence of symptoms directly related to a specific metastasis. Even if a specific site of disease, such as a local recurrence, had the potential to cause symptoms in the future, there was a bias against prophylactic palliation. It was well-established that most patients die of systemic progression. This approach is now under pressure from four directions. Retrospective case series have reported survival durations longer than anticipated in highly selected patients with low-volume, single-organ disease. A randomized phase II trial reported that metastasis-directed therapy prolonged progression-free survival. Biologic data indicate that the site of metastatic relapse is encoded in gene expression profiles already present in the primary tumor. Second-line systemic therapy has become substantially more effective, which lengthens the interval over which control of an untreated metastasis may become clinically important. We trace the oligometastatic concept from the 1995 Hellman and Weichselbaum hypothesis to the 2026 OligoPanc consensus definition of up to three lesions confined to a single organ, examine the criteria proposed for patient selection, summarize the surgical and ablative radiotherapy literature, and consider the trials that will determine whether this is a treatable disease state or a favorable prognostic phenotype. We conclude that induction systemic therapy, followed by response assessment that weighs the absence of disease progression, Carbohydrate Antigen 19-9 (CA19-9) kinetics, and performance status, is a defensible route to local therapy directed at the metastases and the primary tumor, and warrants prospective study.
SN - 2072-6694
ER -